NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND, METHOD FOR OBTAINING SAME, USE THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING

1. A crystalline form of Form II 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole characterized by an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer equipped with a diffracted beam curved graphite monochromator using coppe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CARTER, BARRY, HOWARD, SCHMITT, ERIC, ALLEN, GLOVER, BOBBY, NEAL, RIZZOLIO, MICHELE, CATHERENE, LANCASTER, ROBERT, WILLIAM, SICKLES, BARRY, RIDDLE, HUANG, LIAN-FENG, LONG, STACEY, TODD
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	CHEMISTRY DERIVATIVES THEREOF HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	1. A crystalline form of Form II 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole characterized by an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer equipped with a diffracted beam curved graphite monochromator using copper Kα- X-radiation, wherein said X-ray powder diffraction pattern comprises 2 theta angles at five or more positions selected from the group consisting of at five or more of the following positions 7,91 +- 0,09, 17,33 +- 0,09, 18,23 +- 0,95, 19,60 +- 0,09, 21,88 +- 0,09, 23,24 +- 0,09, 23,92 +- 0,09, 25,27 +- 0,09, 27,70 +- 0,09 and 29,21 +- 0,09 degree . 2. A ethanol solvate 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole characterized by an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer equipped with a diffracted beam curved graphite monochromator using copper Kα- X-radiation, wherein said X-ray powder diffraction pattern comprises 2 theta angles at five or more positions selected from the group consisting of at five or more of the following positions 9,07 +- 0,05, 10,38 +- 0,05, 15,95 +- 0,05, 17,72 +- 0,05, 20,75 +- 0,05, 21,37 +- 0,05, 22,96 +- 0,05, 23,93 +- 0,05, 25,40 +- 0,05 and 29,05 +- 0,05 degree . 3. A crystalline form of Form V 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole characterized by an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer equipped with a diffracted beam curved graphite monochromator using copper Kα- X-radiation, wherein said X-ray powder diffraction pattern comprises 2 theta angles at five or more positions selected from the group consisting of at five or more of the following positions 13,30 +- 0,05, 18,13 +- 0,05, 18,78 +- 0,05, 20,41 +- 0,05, 21,75 +- 0,05, 23,02 +- 0,05, 26,87 +- 0,05, 28,34 +- 0,05, 28,55 +- 0,05 and 30,22 +- 0,05 degree . 4. A composition comprising an admixture of two or more crystalline forms or solvates of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole in accordance with one of Claims 1-3. 5. A composition comprising crystalline form II of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole in accordance with Claim 1 and amorphous 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole. 6. A composition comprising crystalline form I 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazol